Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
Turkish Journal of Anaesthesiology and Reanimation, cilt.50, sa.3, ss.228-231, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 3
- Basım Tarihi: 2022
- Doi Numarası: 10.5152/tjar.2021.20450
- Dergi Adı: Turkish Journal of Anaesthesiology and Reanimation
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.228-231
- Anahtar Kelimeler: Antifibrotic, COVID-19, pirfenidone, pulmonary fibrosis, respiratory distress
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Hayır
Özet
© 2022, AVES. All rights reserved.Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.